Pramlintide or mealtime insulin added to basal insulin treatment in patients with type 2 diabetes

被引：0
|
作者：
Riddle, M. [1 ]
Pencek, R. [2 ]
Charenkavanich, S. [2 ]
Lutz, K. [2 ]
Porter, L. [2 ]
Wilhelm, K. [2 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1007
引用
收藏
页码：S407 / S408
页数：2
相关论文
共 50 条
  • [31] Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes
    Pullman, John
    Darsow, Tamara
    Frias, Juan P.
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2006, 2 (03) : 203 - 212
  • [32] Treatment satisfaction with a basal insulin added to oral agents versus twice-daily premixed insulin alone in patients with type 2 diabetes
    Bradley, C
    Plewe, G
    Kliebe-Frisch, C
    Schweitzer, MA
    Janka, HU
    [J]. DIABETES, 2005, 54 : A304 - A304
  • [33] Lixisenatide added to basal insulin reduces glycaemic variability in patients with type 2 diabetes mellitus
    O'Neal, D.
    Umpierrez, G.
    DiGenio, A.
    Goldenberg, R.
    Hernandez-Triana, E.
    Lin, J.
    Park, C. -Y.
    Renard, E.
    Kovatchev, B.
    [J]. DIABETOLOGIA, 2014, 57 : S342 - S342
  • [34] Basal insulin requirement in insulin treated patients with type 2 diabetes mellitus
    Wiesli, P
    Lehmann, R
    Kraydenbühl, PA
    Schmid, C
    Spinas, GA
    [J]. DIABETES, 2005, 54 : A102 - A102
  • [35] A STEPWISE APPROACH TO INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND BASAL INSULIN TREATMENT FAILURE
    Davidson, Mayer B.
    Raskin, Philip
    Tanenberg, Robert J.
    Vlajnic, Aleksandra
    Hollander, Pricilla
    [J]. ENDOCRINE PRACTICE, 2011, 17 (03) : 395 - 403
  • [36] Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin
    Bolli, Geremia B.
    Porcellati, Francesca
    Meier, Juris J.
    [J]. DIABETES CARE, 2020, 43 (10) : 2333 - 2335
  • [37] Mealtime pramlintide administration reduces early postprandial glucose excursions when added to regular insulin or insulin lispro in patients with diabetes: A dose-timing study.
    Fineman, MS
    Johnson, SB
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P90 - P90
  • [38] Initiation and Gradual Intensification of Premixed Insulin Lispro Therapy Versus Basal ± Mealtime Insulin in Patients With Type 2 Diabetes Eating Light Breakfasts
    Giugliano, Dario
    Tracz, Mariusz
    Shah, Sanjiv
    Calle-Pascual, Alfonso
    Mistodie, Cristina
    Duarte, Rui
    Sari, Ramazan
    Woo, Vincent
    Jiletcovici, Alina O.
    Deinhard, Juergen
    Wille, Simone A.
    Kiljanski, Jacek
    [J]. DIABETES CARE, 2014, 37 (02) : 372 - 380
  • [39] Pramlintide improved glycemic control without increased risk of hypoglycemia in patients with type 2 diabetes using basal insulin
    Lutz, Karen
    Maier, Holly
    Zhang, Bei
    Frias, Juan
    [J]. DIABETES, 2007, 56 : A143 - A143
  • [40] Patient Reported Outcomes in Adults with Type 2 Diabetes Using Mealtime AFRESA™ (Inhaled Technosphere® Insulin) and Basal Insulin Versus Premixed Insulin
    Howard, Campbell P.
    Rubin, Richard R.
    Peyrot, Mark
    [J]. DIABETES, 2009, 58 : A148 - A148
12345